Paper Information

Journal:   AVICENNA JOURNAL OF MEDICAL BIOTECHNOLOGY (AJMB)   JULY-SEPTEMBER 2016 , Volume 8 , Number 3; Page(s) 0 To 0.
 
Paper: 

EDITORIAL: FUTURE DIRECTIONS FOR TRANSLATION OF TISSUE ENGINEERING PRODUCTS INTO CLINIC

 
 
Author(s):  KAZEMNEJAD SOMAIEH*
 
* REPRODUCTIVE BIOTECHNOLOGY RESEARCH CENTER, AVICENNA RESEARCH INSTITUTE, ACECR, TEHRAN, IRAN
 
Abstract: 

At present, Iran has been known one of the up-warding countries in the world in regenerative medicine using stem cells therapy. In fact, the outcomes of some clinical trials on stem cell therapy of myocardial infarction, vitiligo, decompensated cirrhosis, and osteoarthritis narrate the feasibility of stem cell-based therapy for treatment of human diseases 1, 2. However, in a similar manner with global configuration, the commercialization and translation of tissue engineering products into clinical phase has been restricted. It might be due to weak collaboration of different specialties for technology transfer of the multidisciplinary projects of tissue engineering field into clinical phase. Basic tissue engineers mostly prefer elegant studies, whereas physicians have tendency to solve medical problems with products indicating efficiency, easy to use, and cost benefit. Actually, a surgeon encountered with a dilemma between a partially effective tissue-engineered product that is both expensive and difficult to apply and a more traditional approach may choose the latter option.

 
Keyword(s): 
 
References: 
  • ندارد
 
  pdf-File tarjomyar Yearly Visit 64
 
Latest on Blog
Enter SID Blog